167 related articles for article (PubMed ID: 7850793)
1. Cyclophosphamide metabolism in children.
Yule SM; Boddy AV; Cole M; Price L; Wyllie R; Tasso MJ; Pearson AD; Idle JR
Cancer Res; 1995 Feb; 55(4):803-9. PubMed ID: 7850793
[TBL] [Abstract][Full Text] [Related]
2. Phenotypically deficient urinary elimination of carboxyphosphamide after cyclophosphamide administration to cancer patients.
Hadidi AH; Coulter CE; Idle JR
Cancer Res; 1988 Sep; 48(18):5167-71. PubMed ID: 3409242
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.
Chinnaswamy G; Errington J; Foot A; Boddy AV; Veal GJ; Cole M
Eur J Cancer; 2011 Jul; 47(10):1556-63. PubMed ID: 21482104
[TBL] [Abstract][Full Text] [Related]
4. Individual variation in the activation and inactivation of metabolic pathways of cyclophosphamide.
Boddy AV; Furtun Y; Sardas S; Sardas O; Idle JR
J Natl Cancer Inst; 1992 Nov; 84(22):1744-8. PubMed ID: 1433359
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation.
Sladek NE; Doeden D; Powers JF; Krivit W
Cancer Treat Rep; 1984 Oct; 68(10):1247-54. PubMed ID: 6395951
[TBL] [Abstract][Full Text] [Related]
6. Blood levels of alkylating metabolites of cyclophosphamide in the mouse after iv or oral administration.
Struck RF; Alberts DS
Cancer Treat Rep; 1984 May; 68(5):765-70. PubMed ID: 6722832
[TBL] [Abstract][Full Text] [Related]
7. In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Yu LJ; Drewes P; Gustafsson K; Brain EG; Hecht JE; Waxman DJ
J Pharmacol Exp Ther; 1999 Mar; 288(3):928-37. PubMed ID: 10027828
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children.
Boddy AV; Yule SM; Wyllie R; Price L; Pearson AD; Idle JR
Cancer Res; 1993 Aug; 53(16):3758-64. PubMed ID: 8339288
[TBL] [Abstract][Full Text] [Related]
10. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children.
Yule SM; Price L; Pearson AD; Boddy AV
Clin Cancer Res; 1997 Nov; 3(11):1985-92. PubMed ID: 9815588
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and metabolism of cyclophosphamide in paediatric patients.
Tasso MJ; Boddy AV; Price L; Wyllie RA; Pearson AD; Idle JR
Cancer Chemother Pharmacol; 1992; 30(3):207-11. PubMed ID: 1628369
[TBL] [Abstract][Full Text] [Related]
12. Comparative metabolism of 2-[bis(2-chloroethyl)amino]tetrahydro-2-H-1,3,2-oxazaphosphorine-2-oxide (cyclophosphamide) and its enantiomers in humans.
Jarman M; Milsted RA; Smyth JF; Kinas RW; Pankiewicz K; Stec WJ
Cancer Res; 1979 Jul; 39(7 Pt 1):2762-7. PubMed ID: 445480
[TBL] [Abstract][Full Text] [Related]
13. The effect of fluconazole on cyclophosphamide metabolism in children.
Yule SM; Walker D; Cole M; McSorley L; Cholerton S; Daly AK; Pearson AD; Boddy AV
Drug Metab Dispos; 1999 Mar; 27(3):417-21. PubMed ID: 10064575
[TBL] [Abstract][Full Text] [Related]
14. PLasma half-life and urinary excretion of cyclophosphamide in children.
Sladek NE; Priest J; Doeden D; Mirocha CJ; Pathre S; Krivit W
Cancer Treat Rep; 1980; 64(10-11):1061-6. PubMed ID: 7459891
[TBL] [Abstract][Full Text] [Related]
15. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
16. The effect of route of administration and fractionation of dose on the metabolism of ifosfamide.
Lind MJ; Roberts HL; Thatcher N; Idle JR
Cancer Chemother Pharmacol; 1990; 26(2):105-11. PubMed ID: 2347037
[TBL] [Abstract][Full Text] [Related]
17. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy.
Jardine I; Fenselau C; Appler M; Kan MN; Brundrett RB; Colvin M
Cancer Res; 1978 Feb; 38(2):408-15. PubMed ID: 620410
[TBL] [Abstract][Full Text] [Related]
18. Involvement of human glutathione S-transferase isoenzymes in the conjugation of cyclophosphamide metabolites with glutathione.
Dirven HA; van Ommen B; van Bladeren PJ
Cancer Res; 1994 Dec; 54(23):6215-20. PubMed ID: 7954469
[TBL] [Abstract][Full Text] [Related]
19. The determination of cyclophosphamide and its metabolites in blood plasma as stable trifluoroacetyl derivatives by electron capture chemical ionization gas chromatography/mass spectrometry.
Momerency G; Van Cauwenberghe K; Slee PH; Van Oosterom AT; De Bruijn EA
Biol Mass Spectrom; 1994 Mar; 23(3):149-58. PubMed ID: 8148406
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide modulates rat hepatic cytochrome P450 2C11 and steroid 5 alpha-reductase activity and messenger RNA levels through the combined action of acrolein and phosphoramide mustard.
Chang TK; Waxman DJ
Cancer Res; 1993 Jun; 53(11):2490-7. PubMed ID: 8495410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
